Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
van der Graaf, Winette T A × Blay, Jean-Yves Chawla, Sant P Kim, Dong-Wan Bui-Nguyen, Binh Casali, Paolo G Schöffski, Patrick Aglietta, Massimo Staddon, Arthur P Beppu, Yasuo Le Cesne, Axel Gelderblom, Hans Judson, Ian R Araki, Nobuhito Ouali, Monia Marreaud, Sandrine Hodge, Rachel Dewji, Mohammed R Coens, Corneel Demetri, George D Fletcher, Christopher D Dei Tos, Angelo Paolo Hohenberger, Peter EORTC Soft Tissue and Bone Sarcoma Group PALETTE study group #
The Lancet Publishing Group
The Lancet vol:379 issue:9829 pages:1879-1886
Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.